Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
PepGen Inc. | EVP, Head of R&D | Stock Option (Right to Buy) | 243K | Aug 19, 2024 | Direct | ||
ALBIREO PHARMA, INC. | Chief Medical Officer | Restricted Stock Units | 0 | Mar 2, 2023 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
PEPG | PepGen Inc. | Aug 19, 2024 | 2 | $0 | 4 | Aug 20, 2024 | EVP, Head of R&D |
PEPG | PepGen Inc. | Aug 19, 2024 | 0 | $0 | 3 | Aug 20, 2024 | EVP, Head of R&D |
ALBO | ALBIREO PHARMA, INC. | Mar 2, 2023 | 1 | $0 | 4 | Mar 2, 2023 | Chief Medical Officer |
ALBO | ALBIREO PHARMA, INC. | Jan 19, 2023 | 1 | $0 | 4/A | Jan 27, 2023 | Chief Medical Officer |
ALBO | ALBIREO PHARMA, INC. | Dec 19, 2022 | 1 | $0 | 4 | Dec 21, 2022 | Chief Medical Officer |
ALBO | ALBIREO PHARMA, INC. | Dec 19, 2022 | 0 | $0 | 3 | Dec 21, 2022 | Chief Medical Officer |